Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Selinexor is a drug that has been approved in the treatment of patients with symptomatic
multiple myeloma. The standard of care for patients with Smoldering Multiple Myeloma remains
observation, but there are numerous clinical trials investigating interventions to delay
progression to multiple myeloma and prevent or delay disease related outcomes. We know that a
subset of patients with intermediate or high risk smoldering multiple myeloma have a much
higher risk of progressive to multiple myeloma, while the low risk smoldering myeloma patient
population has a much lower risk. This is a clinical trial investigating the use of low-dose
Selinexor in patients with intermediate to high-risk smoldering multiple myeloma. We
hypothesize that the use of Selinexor in intermediate to high risk smoldering myeloma
patients will help to delay progression of disease to symptomatic multiple myeloma.